Therapeutically active compounds and their methods of use
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a purified compound described herein.
1. A method of treating a cancer comprising administering to a patient in need thereof a therapeutically effective amount of a purified compound or a pharmaceutically acceptable salt thereof, wherein the cancer is characterized by the presence of at least one mutation chosen from an IDH1 mutation or an IDH2 mutation and wherein the purified compound is selected from:
2. The method of claim 1 wherein the cancer is selected from glioma (including low grade glioma), glioblastoma (including secondary glioblastoma), grade II or III astrocytoma, grade II or III oligodendroglioma, acute myelogenous leukemia (AML), sarcoma, melanoma, non-small cell lung cancer (NSCLC), cholangiocarcinomas, chondrosarcoma, myelodysplastic syndromes (MDS), myeloproliferative neoplasm (MPN), colon cancer, and angio-immunoblastic non-Hodgkin's lymphoma (NHL) in a patient.
3. The method of claim 2 , wherein the cancer is glioma.
4. The method of claim 3 , wherein the glioma is a low grade glioma or a high grade glioma.
5. The method of claim 1 , wherein the mutation is an IDH1 mutation.
6. The method of claim 5 , wherein the IDH1 mutation is an R132X mutation.
7. The method of claim 6 , wherein the IDH1 mutation is an R132H or R132C mutation.
8. The method of claim 1 , wherein the mutation is an IDH2 mutation.
9. The method of claim 8 , wherein the mutation is a R140X or R172X mutation.
10. The method of claim 9 , wherein the mutation is a R140Q, R140W, or an R140L mutation.
11. The method of claim 9 , wherein the mutation is an R172K or R172G mutation.
12. The method of claim 1 , wherein the amount of the purified compound or pharmaceutically acceptable salt thereof administered to the patient is between about 1 and 5000 mg/day.
13. The method of claim 12 , wherein the amount of the purified compound or pharmaceutically acceptable salt thereof administered to the patient is between about 1 and 1000 mg/day.
14. The method of claim 12 , wherein the amount of the purified compound or pharmaceutically acceptable salt thereof administered to the patient is between about 1 and 500 mg/day.
15. The method of claim 1 wherein the purified compound is administered orally.
16. The method of claim 1 wherein the purified compound or composition is administered in combination with an additional therapeutic modality.
17. The method of claim 16 wherein the additional therapeutic modality is selected from radiation, surgical resection, anti-cancer medications, anti-epileptic medications, anti-seizure medications and anti-emesis medications.
18. The method of claim 17 , wherein the anti-cancer medications are selected from chemotherapy with cytotoxic or cytostatic agents, targeted medications, antibody therapy, immunotherapy and hormonal therapy.
19. A method of treating a cancer comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a purified compound or a pharmaceutically acceptable salt thereof, wherein the cancer is characterized by the presence of at least one mutation chosen from an IDH1 mutation or an IDH2 mutation and wherein the purified compound is selected from:
20. A method of treating a glioma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a purified compound or a pharmaceutically acceptable salt thereof, wherein the glioma is characterized by the presence of at least one mutation chosen from an IDH1 mutation or an IDH2 mutation and wherein the purified compound is selected from:
21. A method of treating a glioma comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a purified compound or a pharmaceutically acceptable salt thereof, wherein the glioma is characterized by the presence of at least one mutation chosen from an IDH1 mutation or an IDH2 mutation and wherein the purified compound is selected from: